Treatment Algorithms in Triple-Negative Breast Cancer: How to Apply them to Clinical Practice : Episode 4
Supportive Care and Managing Toxicities Related to ADCs in TNBC
A panel of medical oncologists provides insights on managing toxicities in patients with triple-negative breast cancer who are receiving antibody-drug conjugates.
Recent Videos
Related Content
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment
June 26th 2025Article
Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.
![TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fbb58c5f3c3692dc35c19320bb63c3df864f9b79b-1500x722.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC")
